Reduction-Responsive Chemo-Capsule-Based Prodrug Nanogel for Synergistic Treatment of Tumor Chemotherapy

Yi Lu,Die Jia,Xianbin Ma,Mengyun Liang,Shengxin Hou,Wei Qiu,Yuan Gao,Peng Xue,Yuejun Kang,Zhigang Xu

DOI: https://doi.org/10.1021/acsami.0c21710

2021-02-10

Abstract:Chemotherapy is currently the most universal therapeutics to tumor treatment; however, limited curative effect and undesirable drug resistance effect are the two major clinical bottlenecks. Herein, we develop a two-in-one cross-linking strategy to prepare a stimuli-responsive prodrug nanogel by virtue of delivering a combination of chemotherapeutic drugs of 10-hydroxy camptothecin and doxorubicin for ameliorating the deficiencies of chemotherapy and amplifying the cancer therapeutic efficiency. The obtained prodrug nanogel has both high drug loading capacity and suitable nanoscale size, which are beneficial to the cell uptake and tumor penetration. Moreover, the chemotherapeutic drugs are released from the prodrug nanogel in response to the reductive tumor microenvironment, enhancing tumor growth inhibition <i>in vitro</i> and <i>in vivo</i> by the synergistic DNA damage. Based on these results, the unique prodrug nanogel would be a promising candidate for satisfactory tumor treatment-based chemotherapy by a simple but efficient strategy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c21710?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c21710</a>.The fluorescence spectra of HSD NGs and control groups; the UV–vis of hemocompatibility; and additional MTT results of HeLa cells, CLSM images, and H&amp;E staining images (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21710/suppl_file/am0c21710_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

This paper aims to address the two major clinical bottlenecks in traditional chemotherapy for tumor treatment: limited therapeutic efficacy and suboptimal drug resistance effects. To improve these issues, the research team developed a "two-in-one" crosslinking strategy to prepare a reduction-responsive prodrug nanogel for the delivery of a combination of 10-Hydroxycamptothecin (HCPT) and Doxorubicin (DOX) to enhance chemotherapy efficacy and improve anticancer effects through synergistic action. This prodrug nanogel possesses high drug loading capacity and appropriate nanoscale size, which facilitates cellular uptake and tumor penetration. Additionally, the chemotherapeutic drugs can be released from the nanogel in the reductive tumor microenvironment, thereby enhancing tumor growth inhibition both in vitro and in vivo. Based on these results, this unique prodrug nanogel is expected to become a promising chemotherapy-based tumor treatment method.